Literature DB >> 29751235

Functionalized spirooxindole-indolizine hybrids: Stereoselective green synthesis and evaluation of anti-inflammatory effect involving TNF-α and nitrite inhibition.

Raju Suresh Kumar1, Paulrayer Antonisamy2, Abdulrahman I Almansour3, Natarajan Arumugam3, Govindasami Periyasami3, Mohammad Altaf4, Ha-Rim Kim2, Kang-Beom Kwon5.   

Abstract

Stereoselective synthesis of a small library of novel spiroheterocyclic hybrids including indolizine, oxindole, and substituted piperidine units has been accomplished in [bmim]Br using a [3 + 2] cycloaddition strategy in good yield and were tested for their anti-inflammatory activities. The effects of compounds (4a-o) against inflammation were studied using carrageenan-induced hind paw oedema, croton oil-induced ear oedema, and cotton pellet-induced granuloma models. Among the heterocyclic hybrids, compounds 4d, 4g, and 4o showed significant anti-inflammatory activities against acute and chronic inflammatory models. These compounds also showed significant inhibition of PGE2, TNF-α, and nitrite levels in carrageenan-induced hind paw oedema. Thus it is evident from our study that these novel spiroheterocyclic hybrids 4d, 4g, and 4o displayed significant anti-inflammatory effects that involve the reduction of PGE2, TNF-α, and nitrite levels.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Inflammation; Ionic liquid; Spiroheterocyclic hybrid; Tumor necrosis factor (TNF-α); [3+2] cycloaddition

Mesh:

Substances:

Year:  2018        PMID: 29751235     DOI: 10.1016/j.ejmech.2018.04.060

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Synthesis and evaluation of ursolic acid-based 1,2,4-triazolo[1,5-a]pyrimidines derivatives as anti-inflammatory agents.

Authors:  Tian-Yi Zhang; Chun-Shi Li; Ping Li; Xue-Qian Bai; Shu-Ying Guo; Ying Jin; Sheng-Jun Piao
Journal:  Mol Divers       Date:  2020-11-17       Impact factor: 2.943

Review 2.  Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.

Authors:  Harbinder Singh; Devendra K Agrawal
Journal:  Bioorg Med Chem       Date:  2022-03-11       Impact factor: 3.461

3.  Design of Novel Enantiopure Dispirooxindolopyrrolidine-Piperidones as Promising Candidates toward COVID-19: Asymmetric Synthesis, Crystal Structure and In Silico Studies.

Authors:  Amani Toumi; Sarra Boudriga; Yasmine M Mandour; Ahmed A Mekki; Michael Knorr; Carsten Strohmann; Jan-Lukas Kirchhoff; Mansour Sobeh
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

4.  Discovery and evaluation of novel synthetic 5-alkyl-4-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1-carbox-amide derivatives as anti-inflammatory agents.

Authors:  Qing-Kun Shen; Guo-Hua Gong; Gao- Li; Mei- Jin; Li-Hua Cao; Zhe-Shan Quan
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Synthesis, in vitro and in vivo biological evaluation of novel lappaconitine derivatives as potential anti-inflammatory agents.

Authors:  Lei Pang; Chun-Yan Liu; Guo-Hua Gong; Zhe-Shan Quan
Journal:  Acta Pharm Sin B       Date:  2019-09-13       Impact factor: 11.413

Review 6.  Transition metal-catalyzed synthesis of spirooxindoles.

Authors:  P V Saranya; Mohan Neetha; Thaipparambil Aneeja; Gopinathan Anilkumar
Journal:  RSC Adv       Date:  2021-02-10       Impact factor: 3.361

7.  TCCA-mediated oxidative rearrangement of tetrahydro-β-carbolines: facile access to spirooxindoles and the total synthesis of (±)-coerulescine and (±)-horsfiline.

Authors:  Manda Sathish; Akash P Sakla; Fabiane M Nachtigall; Leonardo S Santos; Nagula Shankaraiah
Journal:  RSC Adv       Date:  2021-05-05       Impact factor: 4.036

8.  Access to 6-hydroxy indolizines and related imidazo[1,5-a]pyridines through the SN2 substitution/condensation/tautomerization cascade process.

Authors:  Guiyun Duan; Hao Liu; Liqing Zhang; Chunhao Yuan; Yongchao Li; Yanqing Ge
Journal:  RSC Adv       Date:  2021-07-23       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.